Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.

Letizia Porcelli, Annalisa Mazzotta, Marianna Garofoli, Roberta Di Fonte, Gabriella Guida, Michele Guida, Stefania Tommasi, Amalia Azzariti

Research output: Contribution to journalArticlepeer-review


The crosstalk between Notch and MAPK pathway plays a role in MEK inhibitor resistance in BRAFV600E metastatic melanoma (MM) and promotes migration in GNAQQ209L uveal melanoma (UM) cells. We determined the cytotoxicity of combinatorial inhibition of MEK and Notch by cobimetinib and γ-secretase inhibitor (GSI) nirogacestat, in BRAFV600E and BRAF wt MM and GNAQQ209L UM cells displaying different Erk1/2 and Notch activation status, with the aim to elucidate the impact of Notch signaling in the response to MEK inhibitor. Overall the combination was synergic in BRAFV600E MM and GNAQQ209L UM cells and antagonistic in BRAF wt one. Focusing on UM cells, we found that cobimetinib resulted in G0/G1 phase arrest and apoptosis induction, whereas the combination with GSI increased treatment efficacy by inducing a senescent-like state of cells and by blocking migration towards liver cancer cells. Mechanistically, this was reflected in a strong reduction of cyclin D1, in the inactivation of retinoblastoma protein and in the increase of p27KIP1 expression levels. Of note, each drug alone prevented Notch signaling activation resulting in inhibition of c-jun(Ser63) and Hes-1 expression. The combination achieved the strongest inhibition on Notch signaling and on both c-jun(Ser63) and Erk1/2 activation level. In conclusion we unveiled a coordinate action of MAPK and Notch signaling in promoting proliferation of BRAFV600E MM and GNAQQ209L UM cells. Remarkably, the simultaneous inhibition of MEK and Notch signaling highlighted a role for the second pathway in protecting cells against senescence in GNAQQ209L UM cells treated with the MEK inhibitor.

Original languageEnglish
Article number111006
JournalBiomedicine and Pharmacotherapy
Publication statusPublished - Jan 1 2021


  • Cobimetinib (PubChem CID: 16222096)
  • MEK
  • Nirogacestat (PubChem CID:46224413)
  • Notch
  • Senescence
  • Uveal melanoma

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.'. Together they form a unique fingerprint.

Cite this